21 results about "Diabetic rat" patented technology

This invention relates to the field of traditional Chinese medicine (TCM) technology, and more particularly to the application of TCM compositions in the preparation of drugs for the prevention and treatment of diabetes. The TCM composition of this invention includes *Sedum sarmentosum*, seaweed, oyster shell, hawthorn, *Siegesbeckia orientalis*, *Schisandra chinensis*, and *Polygonum cuspidatum*. This invention has found that this composition can significantly reduce blood glucose levels in type 2 diabetic rats and increase serum insulin levels and insulin sensitivity index in rats. Moreover, the compound combination drug for treating diabetes is an existing TCM preparation, safe to use, and its preparation method is simple, rapid, efficient, and easy to operate. The prepared mixtures, tablets, capsules, and micro-pills are easy to carry and convenient to take.

The invention provides a process for preparing a Biochanin A (BCA)-loaded hydroxypropyl methyl cellulose (HPMC) hydrogel aimed at promoting wound healing in diabetic patients. The hydrogel is prepared by dispersing HPMC in distilled water, followed by dissolving BCA into the mixture with continuous stirring, then storing under refrigeration. The therapeutic potential of Biochanin A (BCA) in promoting wound healing, is evaluated in rats induced with diabetes. The results showed that the BCA-loaded hydrogel accelerates diabetic wound repair by boosting antioxidant defenses via upregulating Nrf2 and related enzymes, suppressing inflammatory markers such as IL-1β, IL-6, TNF-α, COX-2, and TLR4, and stimulating angiogenesis through increased expression of TGF-β1, VEGF-A, and PDGFR. It promotes faster wound contraction, re-epithelialization, collagen deposition, granulation tissue formation, and neovascularization, potentially reducing the risk of complications like limb amputation. The invention offers a promising therapeutic approach for treating chronic diabetic wounds with improved healing outcomes.

The present application belongs to the field of biological medicine, and relates to an in-situ spraying particle-gel composite as well as a preparation method and application thereof. The present application prepares a drug-loaded particle-gel composite material, which can be rapidly gelled in-situ in the form of spraying. In a wound infection model of diabetic rats, the composite material exhibits good photothermal activation TRPV1 channel-mediated local analgesia, as well as anti-inflammatory, antibacterial, antioxidant, hemostatic and wound healing-promoting multifunctional therapeutic effects. Through in-vitro and in-vivo material characterization, as well as histopathological examination of animal experiments, it is confirmed that the composite gel material has good biological safety and degradability, and is a local anesthetic biomaterial preparation which is expected to be clinically transformed for chronic wound analgesia and healing-promoting therapeutic effects.

The present application relates to a kind of porous scaffold for repairing bone defect loaded with black phosphorus active oxygen elimination and slow-release drug and its preparation method;The scaffold includes the amino cation polymer grafted with the phenylboronic acid (PBA) and cyclodextrin (CD) that can eliminate active oxygen, black phosphorus nanosheet (BP) and scaffold material poly (lactic acid-glycolic acid) (PLGA).The porous scaffold loads a large number of black phosphorus nanosheet that can be hydrolyzed into bone repair nutrients, and the porous structure provides sufficient space for cell migration and growth, realizes the good repair of bone.Active oxygen elimination ability, can eliminate active oxygen in diabetic microenvironment.In addition, cyclodextrin can load a variety of drugs, such as osteogenic differentiation induction drug, and realize the slow release of drug.The porous scaffold has good biocompatibility, and the degradation product is harmless to human body, can be used for the tissue repair of bone defect, can be widely applied in the field of biological medicine and tissue engineering, and has been proved to have good repair ability in the diabetic rat skull defect model.

The invention discloses eye drops for treating vascular hyperplasia of eyes and a preparation method of the eye drops, and belongs to the technical field of biological pharmacy. The eye drops comprise a recombinant human angiostatin protein, an endostatin protein and a pharmaceutically acceptable carrier, wherein the recombinant human angiostatin protein and the endostatin protein are used for preparing the eye drops. Experiments show that the eye drops show remarkable vascular inhibition activity in a chick embryo chorioallantoic membrane model and a diabetic rat retina hyperplasia model, and the two proteins are combined for use to achieve a synergistic effect; the invention provides a safe and effective new way for local treatment of ocular vascular hyperplasia diseases.

The application belongs to the field of biomedical materials, and discloses a multifunctional hydrogel suitable for diabetic wound healing. The hydrogel is compounded by HA-Tris, EPL-Cpb and MXene / Mn composite nanoparticles in a mass ratio of 2:1:(0-0.2), and is rapidly crosslinked in 1 min through a triple mechanism, with a crosslinking efficiency increased by more than 80% compared with traditional methods and a yield of more than 99.5%. The application realizes chemical-photothermal dual-mode antibiosis through precise optimization of the ratio and reaction conditions and the function synergy of the components, with an inhibition rate of 96.86% and 97.23% for Escherichia coli and Staphylococcus aureus, which is increased by more than 62% compared with traditional silver-containing dressings; the hydrogel has a ROS clearance rate of 92.5% and an in-situ oxygen production rate increased by 58% compared with traditional methods, and can efficiently stop bleeding within 30 s, with a blood loss reduced by 90.3% compared with the blank group. The hydrogel has excellent biocompatibility and can comprehensively improve the pathological microenvironment of diabetic wounds, shortening the healing period of full-thickness skin wounds of diabetic rats from 21 days to 10 days, and providing a new and efficient biomedical material for the treatment of diabetic wounds.

The invention relates to application of a near-infrared light source or a blue light source in preparation of equipment for treating diabetes, and belongs to the technical field of photomedicine. The invention provides application of a near-infrared light source or a blue light source in preparation of equipment for treating diabetes. According to the invention, a diabetic rat model is established, near-infrared light and blue light are adopted to carry out phototherapy on diabetic rats, and blood sugar and blood fat related indexes of the diabetic rats and changes of different tissue forms and behaviors of the rats are measured; results show that the near-infrared light and the blue light can effectively improve blood sugar and blood fat related indexes of the rats after phototherapy of the rats, and can also improve tissue morphology and cognitive behaviors of the diabetic rats, which indicates that the phototherapy of the near-infrared light or the blue light has the effects of treating diabetic blood sugar and cognition, can reduce dependence of patients on medicines, and can improve the curative effect of the patients on diabetes mellitus. And new experimental basis and theoretical support are provided for clinical non-drug intervention of diabetes.

The application discloses a novel brown algae polysaccharide SARP for promoting healing of diabetic ulcers and a preparation and application thereof. A novel SARP is obtained through Sephacryl S-300 / HR gel column separation and purification, and the molecular weight of the SARP is about 45.4 kDa, which is composed of mannuronic acid (76.56%), guluronic acid (18.89%) and a small amount of glucuronic acid (4.55%). Compared with alginate separated from other brown algae, the SARP has a higher content of mannuronic acid. The SARP shows a better in-vitro antioxidant capacity, and can obviously reverse the cell damage of HUVECs caused by H2O2 and high sugar in the HUVECs. In addition, the SARP can promote the migration and tubular formation of the HUVECs. In-vivo experiments further show that the SARP can promote the healing of diabetic ulcer in rats, and can reduce the oxidative stress, inflammation level and lipid disorder in the rats. The SARP has a simple purification route, can be prepared in a large amount, and is a very promising novel drug for treating diabetic foot ulcers.

The application belongs to the technical field of traditional Chinese medicine preparation, and discloses a traditional Chinese medicine composition, a preparation method and application thereof. One of the traditional Chinese medicine compositions comprises the following raw materials in parts by weight: Cyclobalanopsis glauca 50-80 parts, tartary buckwheat 30-50 parts, polygonatum 30-50 parts, honeysuckle 30-50 parts, Poria cocos 10-20 parts, gordon euryale seed 10-20 parts, lotus seed 10-20 parts, medlar 10-20 parts, angelica 10-20 parts, yam 5-15 parts, hawthorn 5-15 parts, and sour jujube seed 5-15 parts. The compound preparation has a good blood glucose-lowering effect, can correct the lipid metabolism disorder of diabetic rats, and reduce liver function damage, has a certain protective effect on the liver, and can be applied to the preparation of a medicine for treating non-alcoholic fatty liver. On this basis, in addition to adding part of the medicinal materials, the traditional Chinese medicine composition can also be applied to the preparation of a medicine for treating chronic obstructive pulmonary disease and a medicine for treating bacterial pneumonia.

The invention belongs to the field of development and utilization of beautiful millettia roots, and particularly relates to a beautiful millettia root flower extract and a preparation method and application thereof. Fresh flower buds in the initial flowering period of beautiful millettia roots are adopted as raw materials, fermentation liquor is prepared through fermentation of lactobacillus, lactobacillus casei and lactobacillus acidophilus, after sterilization, cellulase, pectin lyase and cellobiohydrolase are added for enzymolysis, enzymatic hydrolysate is obtained, after enzyme deactivation of the enzymatic hydrolysate, alcohol precipitation is conducted to remove precipitates, and the finished product is obtained. The prepared millettia specisoa flower extract can reduce blood sugar of rats with type 2 diabetes mellitus and regulate intestinal flora of the rats, and a new candidate medicine is provided for treatment of diabetes mellitus.

The invention provides a magnesium oxide-loaded asymmetric short fiber aerogel scaffold as well as a preparation method and application thereof, and belongs to the technical field of tissue engineering materials. The preparation method comprises the following steps: adding MgO nanoparticles into a PLLA / Gelatin solution, and carrying out electrostatic spinning, crushing, freeze drying and crosslinking to obtain the porous short fiber aerogel scaffold (GP-coated MgO). The GP-coated MgO aerogel stent has a three-dimensional short fiber structure, and can release loaded MgO nanoparticles in a progressive and continuous manner while wound exudate is slowly absorbed. In-vivo and in-vitro experiments prove that the GP-coated MgO aerogel scaffold has biocompatibility and is very effective in the aspects of inhibiting inflammatory response and slowing down cell senescence. In addition, the GP-coated MgO significantly accelerates vascular reconstruction and epithelization, and promotes wound repair at the skin defect position of a diabetic rat.

The invention belongs to the technical field of functional food, and particularly relates to a composition beneficial to maintaining the healthy level of blood sugar and a preparation method and application of the composition. The composition helpful for maintaining the healthy level of blood sugar is prepared from the following components in parts by weight: 5-25 parts of fermented soya bean powder, 1-10 parts of cinnamon powder and 1-10 parts of emblic leafflower fruit powder. The cinnamon powder, the fermented soya bean powder and the emblic leafflower fruit powder in a specific dosage relationship are matched, so that the cinnamon powder, the fermented soya bean powder and the emblic leafflower fruit powder generate a synergistic interaction effect. Experiments prove that the composition provided by the invention can improve the alpha-glucosidase inhibition rate, greatly reduce the fasting blood glucose and insulin resistance index of diabetic rats, and contribute to maintaining the healthy level of blood glucose.

This invention belongs to the field of experimental animal model construction technology, specifically relating to the construction method and application of a recombinant inbred type 2 diabetic rat model. The parent rats are SD (fa+ / +) or Wistar (fa+ / +) females and Zucker (fa+ / -) males. Heterozygous (fa+ / -) female offspring are backcrossed with the fathers until the F6 generation. Then, F6 heterozygous (fa+ / -) female rats are crossed with F6 heterozygous (fa+ / -) male rats. The resulting homozygous (fa- / -) SD / Zucker or Wistar / Zucker rats are the recombinant inbred type 2 diabetic rats. The rats obtained by this invention do not express functional leptin receptors, exhibit hyperphagia, and spontaneous polydipsia and polyphagia, which closely resembles the real-world scenario of type 2 diabetes caused by overnutrition under normal dietary conditions in humans.

The invention provides a preparation method of medical titanium of a silicon dioxide and Prussian blue nano-particle composite coating with multiple biological functions and a medical titanium product obtained by the method aiming at the defects that an existing titanium implant surface modification technology is single in function and difficult to adapt to a complex pathological environment. The invention also discloses application of the medical titanium product in a diabetic rat maxilla implantation experiment.

This invention provides the application of transcription factor CUX1 in the preparation of products for the prevention and treatment of diabetic foot ulcers, belonging to the field of biomedical technology. Its key technical point lies in providing the application of transcription factor CUX1 as a target in the preparation of products for the prevention and treatment of diabetic foot ulcers. This application confirms the high expression of transcription factor CUX1 in diabetic foot ulcer wound tissue through specific verification experiments. Using a diabetic rat model of ischemic foot ulcers in the lower limbs, this invention is the first to clearly demonstrate a significant increase in the expression of transcription factor CUX1 in diabetic ulcer wound tissue. Using a high-glucose, high-lipid cell injury model, it is the first to demonstrate that CUX1 expression is significantly high after fibroblast injury due to high glucose and high lipid levels. It is the first to discover that transcription factors have a protective effect on fibroblasts injured by high glucose and high lipid levels. This invention provides a new approach for the treatment of diabetic foot ulcers and a new target for the development of diabetic wound healing.

The application discloses a new application of mulberry polysaccharide in preparation of a medicine for treating type 2 diabetes by regulating intestinal flora, and belongs to the technical field of medicinal and edible plant polysaccharides. In the application, a type 2 diabetes rat model is constructed by using high-sugar and high-fat feed in combination with streptozotocin, biochemical index detection, liver HE staining and oil red O staining, intestinal flora 16S rRNA high-throughput sequencing, and GC-MS detection of short-chain fatty acid content are carried out, so as to confirm that the mulberry polysaccharide can regulate the intestinal flora structure of T2DM rats, improve the secretion level of short-chain fatty acids, improve insulin resistance and glycolipid metabolism disorder, enhance the antioxidant capacity of the body, and repair the pathological damage of the liver. The application clearly defines the anti-type 2 diabetes mechanism of the mulberry polysaccharide, which takes the intestinal flora-short-chain fatty acid axis as the core. The mulberry polysaccharide is a natural low-toxicity medicinal and edible active ingredient, has no side effects of chemical hypoglycemic drugs, can be prepared into various oral medicine dosage forms, and is used for the prevention and clinical treatment of type 2 diabetes, so the application prospect is wide.

A compound represented by formula (I) and a preparation method thereof, and a pharmaceutically acceptable salt thereof, a metabolic precursor thereof, a metabolite thereof, an isomer thereof or a prodrug thereof; experiments show that the indole alkaloid not only promotes axon growth of peripheral sensory neurons, improves the nerve conduction velocity and anesthesia symptom of diabetic rats, but also promotes healing of foot ulcer wounds of diabetic rats, thus having good therapeutic effects on diabetic complication peripheral neuropathy and diabetic feet; they also show that the indole alkaloid also obviously reduces a degree of pulmonary fibrosis induced by bleomycin in mice, and plays a role in protecting lung tissues.

This invention relates to the field of biomedical technology, and particularly to a method and application for identifying active ingredients for the prevention and treatment of diabetes from non-medicinal Astragalus membranaceus slices. The method includes: first, qualitative and quantitative analysis of the chemical components of Astragalus membranaceus and longan slices; second, evaluation of its hypoglycemic efficacy using a diabetic rat model to verify the effects of Astragalus membranaceus and longan slices in lowering blood sugar, improving insulin resistance, and reducing inflammation; and finally, integration of non-targeted and pseudo-targeted metabolomics technologies to systematically identify the core active ingredients in key pathways for the prevention and treatment of diabetes by analyzing the correlation between chemical components and efficacy indicators. This invention not only reveals the main pharmacodynamic substances of Astragalus membranaceus in the prevention and treatment of diabetes, but also provides a theoretical basis and technical support for the development of related functional products or innovative drugs, and for comprehensively improving the utilization efficiency and economic value of Astragalus membranaceus resources.

The invention relates to the technical field of biological medicine, in particular to application of troxerutin in preparation of a medicine for improving dyslipidemia. According to the application disclosed by the invention, in a streptozotocin-induced type 2 diabetes rat model, the intervention of troxerutin for seven weeks generates a remarkable and dose-dependent improvement effect, and the effect of troxerutin reaches a level which can be compared with or even better than that of a reference drug metformin (10 mg / kg / day). And the troxerutin is derived from a natural plant, the water-soluble characteristic of the troxerutin is beneficial to absorption and metabolism, and no obvious adverse reaction is observed in the experimental period of the invention, which indicates that the troxerutin has better safety than many synthetic drugs.

The application discloses a kind of stem cell exosome based on targeted fusion polypeptide modification, preparation method and its application in treating male erectile dysfunction.The exosome is anchored on the surface by chemical coupling technology with specific targeted fusion polypeptide (sequence: EPLQLKM-GGGGS-DPPV), which enhances its targeting to cavernosal smooth muscle cells;At the same time, by loading anti-TrkA monoclonal antibody (TrkA-2E7-HL) through electroporation method, the fibrosis pathway mediated by nerve growth factor (NGF) is inhibited.The exosome is induced by antioxidant culture medium to induce umbilical cord mesenchymal stem cells to secrete, which significantly improves its antioxidant activity.Experiments show that the erectile function (ICP / MAP ratio) of the exosome after modification is increased to 0.79±0.05 in a diabetic ED rat model, the fibrosis area is reduced to 9.2±1.6%, and the NO secretion level is increased by 3.5 times compared with ordinary exosome.The application realizes effective reversal of ED pathological process through polypeptide targeting, antibody synergy and antioxidant triple mechanism, and has significant novelty and clinical transformation potential.

The invention discloses pacific oyster galactose / rhamnose binding lectin CGL-1 recombinant protein as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. In a diabetic rat model, the CGL-1 recombinant protein can significantly promote the healing of MRSA infectious wounds, and the healing rate reaches 92.44%-94.51%. Histological analysis shows that inflammatory cell infiltration of a wound surface of a CGL-1 treatment group is reduced, collagen deposition is increased, neovascularization is good, and a good healing effect is shown. In addition, the bacterial quantity of a wound surface of a CGL-1 treatment group is obviously lower than that of a model group, and the bacterial quantity is respectively reduced by 25.3%-88.55% and 68.45%-95.83% on the fifth day and the thirteenth day. The results show that the CGL-1 lectin protein has the potential of serving as a novel non-antibiotic therapeutic agent, can be used for treating diabetes infected wounds, and provides a new thought for application of marine biological resources in the field of wound healing.